delay impact lower new patient start expect recur
revenu strong momentum drive near-term revenu
report strong beat help new
omnipod patient start hit record start dash drive new
start type patient make new start also stock
quarter patient prepar lockdown move low end
prior guidanc rang offer detail outlook call declin
new patient start dynam expect continu throughout rest
year new patient start histor make revenu quarter
podd revenu larg shelter recur natur current user renew
prescript macroeconom pressur could limit new start think
well-suit withstand sinc busi model requir years-
long commit patient pay up-front cost hardwar also
broad insur coverag new patient assist program help allevi
pain time horizon push back slightli manag
anticip limit releas market prior time earli
revis model reflect guidanc believ remain posit
strength grow rapidli post-pandem remain neutral base valuat
look weather storm strategi includ no-money
up-front demo program strong insur coverag new custom
assist program new patient start key metric watch go
forward abil continu add user crucial compani good
insur coverag medicar medicaid beneficiari
dash cover commercially-insur measur
togeth help shield recessionari pressur like unemploy
loss health coverag
omnipod dash sale expand pharmaci channel spur record patient
start manag report dash drove new patient
nearli patient came pharmaci channel overal
 custom come product pharmaci lend
credibl strategi one seen across space move lower-
friction model last month secur coverag pharmaci channel
support trend
fda approv beyond horizon compani recent sent softwar
patch horizon autom glucos control system fda review
fold agenc review time clinic site logist expect trial restart
june manag track bring horizon us market limit releas
first half
valuat rate neutral risk discuss
factset btig estim compani
document million except per share amount
like differenti omnipod tubeless insulin deliveri lower up-front cost potenti new reimburs
opportun potenti drug deliveri upsid compani improv gross margin grown instal base
continu expand think devic littl direct competit dash platform improv patient
experi longer term horizon expand product offer want autom insulin deliveri howev
neutral rate base valuat trade sever turn fast-grow comp group
updat disrupt
updat dash adopt shift pharmaci channel payor coverag
horizon loop trial regulatori updat
on-going competit launch autom insulin deliveri system
announc new drug deliveri product
pandem resolv mid-summ gradual recoveri follow
increas adopt diabet technolog
improv gross margin oper margin
strong clinic data horizon and/or loop system
rapid resolut pandem faster recoveri afterward
revenu growth rate meaning higher
explos growth adopt diabet technolog favor simpl streamlin
acceler improv gross margin oper margin
significantli better clinic data horizon and/or loop vs competit product
pandem last longer slower littl recoveri afterward
revenu growth rate meaning lower
slow adopt diabet technolog
littl improv gross margin oper margin
disappoint clinic data horizon and/or loop system
bodi
worn
insulet corpor make sell
approxim three day time
use manag
wear number cumbersom
compon includ inch
tube contrast omnipod
use devic elimin need
bulki pump tube separ blood
glucos meter provid virtual
commun wirelessli integr
top total revenu forecast bring due out-performance omnipod revenu
intern omnipod beat gross margin bp higher model compani continu
expand manufactur capac facil global suppli chain sg spend percentag revenu came
combin bp estim spend likewis bp higher estim combin
oper margin bp project
mainli higher oper expens net loss came oppos project net
incom loss per share seven cent lower forecast
revis forecast account guidanc overal revenu forecast chang much
 cut gross margin adjust oper spend expect hit gross margin model
revenu non-gaap ep
insulet rate neutral continu like compani market posit lack near-term competit price
payor statu product pipelin believ stock fairli valu time btig provid price target
neutral-r stock risk includ interrupt horizon data timelin disrupt intern revenu
instal patient base increas competit potenti prefer partnership major insur group lack
visibl next drug deliveri product
btig cover compani mention report
appendix analyst certif import disclosur
